{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:34:46Z","timestamp":1791178486574,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant\/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 DASISION trial, patients with newly diagnosed chronic-phase (CP) CML were randomized to receive dasatinib 100 mg (n = 259) or imatinib 400 mg (n = 260) once daily. Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR). Here, 24-month data are presented. Cumulative response rates by 24 months in dasatinib and imatinib arms were: CCyR in 86% versus 82%, MMR in 64% versus 46%, and BCR-ABL reduction to \u2264 0.0032% (4.5-log reduction) in 17% versus 8%. Transformation to accelerated-\/ blast-phase CML on study occurred in 2.3% with dasatinib versus 5.0% with imatinib. BCR-ABL mutations, assessed after discontinuation, were detected in 10 patients in each arm. In safety analyses, fluid retention, superficial edema, myalgia, vomiting, and rash were less frequent with dasatinib compared with imatinib, whereas pleural effusion and grade 3\/4 thrombocytopenia were more frequent with dasatinib. Overall, dasatinib continues to show faster and deeper responses compared with imatinib, supporting first-line use of dasatinib in patients with newly diagnosed CML-CP. This study was registered at ClinicalTrials.gov: NCT00481247.<\/jats:p>","DOI":"10.1182\/blood-2011-08-376087","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T23:48:14Z","timestamp":1323474494000},"page":"1123-1129","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":500,"title":["Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)"],"prefix":"10.1182","volume":"119","author":[{"given":"Hagop M.","family":"Kantarjian","sequence":"first","affiliation":[{"name":"The University of Texas M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[{"name":"University of California\u2013San Francisco School of Medicine, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"The University of Texas M. D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology \u201cL. and A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan B.","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Institute of Medical Sciences, Bombay Hospital, Mumbai, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Soledad","family":"Undurraga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital del Salvador, Santiago, Chile;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, Institute of Hematology and Blood Diseases Hospital, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Julio","family":"Kassack Ipi\u00f1a","sequence":"additional","affiliation":[{"name":"Hospital General de Mexico, Mexico City, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Pavlovsky","sequence":"additional","affiliation":[{"name":"FUNDALEU, Ang\u00e9lica Ocampo Hospitalization and Clinical Research Center, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Rostock, Rostock, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge H.","family":"Milone","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Italiano de La Plata, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck E.","family":"Nicolini","sequence":"additional","affiliation":[{"name":"Hematology Department, Edouard Herriot Hospital, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Van Droogenbroeck","sequence":"additional","affiliation":[{"name":"Department of Haematology, AZ St Jan Hospital, Brugge, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edo","family":"Vellenga","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brigid","family":"Bradley-Garelik","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Wallingford, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Wallingford, CT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Abteilung H\u00e4matologie\/Onkologie, Universit\u00e4tsklinikum Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2019111807395929500_B1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Goldman","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111807395929500_B2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3324\/haematol.2008.001214","article-title":"Treatment of chronic myeloid leukemia in blast crisis.","volume":"93","author":"Hehlmann","year":"2008","journal-title":"Haematologica"},{"issue":"23","key":"2019111807395929500_B3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111807395929500_B4","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract].","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"20","key":"2019111807395929500_B5","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111807395929500_B6","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"2019111807395929500_B7","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.6512","article-title":"Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib [abstract].","volume":"29","author":"Shah","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111807395929500_B8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111807395929500_B9","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111807395929500_B10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2019111807395929500_B11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111807395929500_B12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111807395929500_B13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111807395929500_B14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"25","key":"2019111807395929500_B15","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2019111807395929500_B16","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS).","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111807395929500_B17","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111807395929500_B18","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111807395929500_B19","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111807395929500_B20","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/sj.leu.2403033","article-title":"Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.","volume":"17","author":"Paschka","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"2019111807395929500_B21","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"issue":"24","key":"2019111807395929500_B22","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111807395929500_B23","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111807395929500_B24","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111807395929500_B25","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"issue":"13","key":"2019111807395929500_B26","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111807395929500_B27","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"issue":"22","key":"2019111807395929500_B28","article-title":"Opportunistic infections are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract].","volume":"114","author":"Al-Ameri","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"2019111807395929500_B29","article-title":"Low risk of infectious events in patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) treated with dasatinib [abstract].","volume":"114","author":"Al-Ameri","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111807395929500_B30","article-title":"A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial [abstract].","volume":"116","author":"Radich","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/5\/1123\/1356096\/zh800512001123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/5\/1123\/1356096\/zh800512001123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:49:51Z","timestamp":1574063391000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/5\/1123\/29777\/Dasatinib-or-imatinib-in-newly-diagnosed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,2]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,2,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-08-376087","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,2]]}}}